Oncology News

Enrollment for the Pan-European SORAMIC clinical trial, a study that will investigate the safety and efficacy of Nexavar combined with SIR-Spheres for the treatment of primary hepatocellular carcinoma, is now complete, according to a press release.

Patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogues showed a reduced risk for hepatocellular carcinoma recurrence compared with patients untreated with nucleos(t)ide analogues, according to published findings.

The overall incidence and mortality rates for cancer have decreased over the years, according to the newly released Annual Report to the Nation on the Status of Cancer.

Patients with hepatocellular carcinoma admitted to the hospital on the weekend had an increased likelihood for mortality vs. patients admitted on a weekday, according to data presented at the Society of Hospital Medicine Annual Meeting 2016.

Celsion Corporation announced the launch of the OPTIMA study for primary hepatocellular carcinoma in China, which will investigate the safety and efficacy of ThermoDox plus radiofrequency ablation, according to a press release.

In the SHELTER clinical trial, patients with hepatocellular carcinoma treated with Nexavar in combination with resminostat had efficacious treatment rates vs. resminostat alone, according to data published in the Journal of Hepatology.

Researchers found that MEP1A, a candidate oncogene, is a novel predictor of hepatocellular carcinoma and impacted the development and rate of progression of the disease, according to published findings in Hepatology.

In a prospective cohort study, patients with hepatocellular carcinoma who underwent anatomic resection had decreased risk for recurrence compared with patients who did not, according to data published in the Journal of Hepatology.

In a U.S. Veteran population, a majority of patients with hepatocellular carcinoma had undetected cirrhosis at the time carcinoma was diagnosed. These patients were also more likely to have advanced stage HCC.

SAN FRANCISCO — Programmed death-1 blockade demonstrated promising activity in mismatch repair deficient gastrointestinal cancers in a phase 2 trial, according to data presented at the Gastrointestinal Cancers Symposium.